These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Prognostic factors in the treatment of multiple myeloma]. Antipova LG Ter Arkh; 1983; 55(8):59-63. PubMed ID: 6635958 [No Abstract] [Full Text] [Related]
30. Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapy. Alexanian R; Migliore PJ J Lab Clin Med; 1970 Feb; 75(2):225-33. PubMed ID: 5414404 [No Abstract] [Full Text] [Related]
31. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253 [TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. Jaksic W; Trudel S; Chang H; Trieu Y; Qi X; Mikhael J; Reece D; Chen C; Stewart AK J Clin Oncol; 2005 Oct; 23(28):7069-73. PubMed ID: 16129840 [TBL] [Abstract][Full Text] [Related]
33. [Prognosis of Kahler's disease in patients treated and not treated with alkylating agents (apropos of 45 cases)]. Saporta L; Hugon C; Rondier J; Bontoux D; Delbarre F Rev Rhum Mal Osteoartic; 1972 Jan; 39(1):11-8. PubMed ID: 5079686 [No Abstract] [Full Text] [Related]
34. [Multiple myeloma of the bone]. Facon T Rev Prat; 2002 Jan; 52(1):63-70. PubMed ID: 11852769 [No Abstract] [Full Text] [Related]
35. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. Talamo G; Angtuaco E; Walker RC; Dong L; Miceli MH; Zangari M; Tricot G; Barlogie B; Anaissie E J Clin Oncol; 2005 Aug; 23(22):5217-23. PubMed ID: 15955903 [TBL] [Abstract][Full Text] [Related]
36. [Clinical aspects of multiple myeloma and its treatment based on a 10-year clinical experience]. Bach I Orv Hetil; 1972 Apr; 113(17):981-5. PubMed ID: 5022591 [No Abstract] [Full Text] [Related]
37. A simple screening procedure for detection of infraclinical cases of multiple myeloma. Pandey J; Kothari SY; Lata K; Talib VH; Shrivastava RK Indian J Pathol Microbiol; 1993 Oct; 36(4):453-7. PubMed ID: 8157315 [TBL] [Abstract][Full Text] [Related]
38. Health-related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: a retrospective analysis. Slovacek L; Slovackova B; Pavlik V; Hrstka Z; Macingova Z; Jebavy L; Horacek JM Neoplasma; 2008; 55(4):350-5. PubMed ID: 18505348 [TBL] [Abstract][Full Text] [Related]
39. [Acute myeloproliferative syndrome after alkylating agent treatment in a case of multiple myeloma]. Gardella S; Cervantes F; Bladé J; Brugués R; Rozman C Med Clin (Barc); 1982 Sep 1-15; 79(4):185-8. PubMed ID: 7144293 [No Abstract] [Full Text] [Related]
40. Intensification of the stem cell transplant induction regimen results in increased treatment-related mortality without improved outcome in multiple myeloma. Abraham R; Chen C; Tsang R; Simpson D; Murray C; Davidson M; Meharchand J; Sutton DM; Crump RM; Keating A; Stewart AK Bone Marrow Transplant; 1999 Dec; 24(12):1291-7. PubMed ID: 10627637 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]